EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacogenetics Approach for Personalized Tacrolimus Dosing in Heart Transplantation: A Case Report and Literature Review

Nives Nikpalj, Jure Samardžić, Nada Božina, Livija Šimičević iD, Lana Ganoci, Tamara Božina iD

Genes · 2025

DOI: 10.3390/genes16091010 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Genes, 2025. Verfasst von Nives Nikpalj und 5 weiteren Autor:innen. Beteiligte Einrichtung: General Hospital Zadar, 23000 Zadar, Croatia. Hauptthemen laut MEDLINE: Tacrolimus, Heart Transplantation, Cytochrome P-450 CYP3A, Immunosuppressive Agents. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Croatian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tacrolimus is a cornerstone of immunosuppressive therapy following heart transplantation. Despite routine therapeutic drug monitoring (TDM), substantial interindividual variability in tacrolimus pharmacokinetics presents a persistent challenge. Pharmacogenetic profiling—particularly of CYP3A5 and CYP3A4 polymorphisms—offers a promising approach to individualize tacrolimus dosing and improve clinical outcomes. Case Presentation: We describe a 54-year-old male heart transplant recipient with persistently subtherapeutic tacrolimus trough concentrations despite escalating standard doses. Tacrolimus dosing initially started at 3.5 mg twice daily, escalated to 7.0 mg twice daily, with final maintenance dosing at 6.5 mg twice daily. TDM values were persistently subtherapeutic at 3–5 ng/mL for over a month before achieving therapeutic targets >10 ng/mL. Pharmacogenetic testing revealed a CYP3A5 expresser genotype (*1/*3) and normal CYP3A4 activity (*1/*1), suggesting enhanced metabolic clearance. In accordance with CPIC guidelines, tacrolimus dosing was intensified and supported by co-administration of diltiazem (60 mg twice daily, later adjusted to 90 mg twice daily), a CYP3A4 inhibitor. Subsequent TDM confirmed achievement of therapeutic levels. At nine months post-transplant, the patient exhibited stable graft function and excellent clinical status.

Discussion

This case underscores the value of genotype-informed tacrolimus dosing in clinical scenarios where standard TDM is insufficient. Pharmacogenetic variation—particularly involving CYP3A5 expression—has been consistently associated with altered tacrolimus exposure and dose requirements. The literature supports routine genotyping in solid organ transplant recipients, although implementation remains limited. Additional considerations include drug–drug interactions, notably with CYP3A-modulating agents such as diltiazem and antifungals, which may further influence tacrolimus pharmacokinetics. Current evidence suggests that the utility of CYP3A4 genotyping may be phase-dependent, being more impactful during early post-transplant periods.

Conclusions

Incorporating pharmacogenetic data alongside TDM facilitates more precise and individualized tacrolimus therapy, optimizing immunosuppressive efficacy and minimizing risk. This case, supported by literature review, advocates for broader integration of genotype-guided strategies in transplant pharmacotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusHeart TransplantationCytochrome P-450 CYP3AImmunosuppressive AgentsHumansMaleMiddle AgedPharmacogeneticsPrecision MedicineDrug MonitoringDiltiazem

Stichwörter der Autor:innen

CYP3A4CYP3A5drug–drug interactionsgenotype-guided dosingheart transplantationpersonalized medicinepharmacogeneticstacrolimus

Substanzen

TacrolimusCytochrome P-450 CYP3AImmunosuppressive AgentsCYP3A5 protein, humanDiltiazemCYP3A4 protein, human

Autor:innen und Institutionen

  • General Hospital Zadar, 23000 Zadar, Croatia.
  • Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
  • Department of Cardiovascular Diseases, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
  • Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
  • Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
  • Department of Chemistry and Biochemistry, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.

ORCID-Profile: Livija Šimičević, Tamara Božina

Förderung

  • Croatian Science Foundation

Zitieren

APA

Nikpalj, N., Samardžić, J., Božina, N., Šimičević, L., Ganoci, L., & Božina, T. (2025). Pharmacogenetics Approach for Personalized Tacrolimus Dosing in Heart Transplantation: A Case Report and Literature Review. Genes. https://doi.org/10.3390/genes16091010

Vancouver

Nikpalj N, Samardžić J, Božina N, Šimičević L, Ganoci L, Božina T. Pharmacogenetics Approach for Personalized Tacrolimus Dosing in Heart Transplantation: A Case Report and Literature Review. Genes. 2025. doi:10.3390/genes16091010

BibTeX
@article{Nikpalj2025,
  author = {Nikpalj, Nives and Samardžić, Jure and Božina, Nada and Šimičević, Livija and Ganoci, Lana and Božina, Tamara},
  title = {Pharmacogenetics Approach for Personalized Tacrolimus Dosing in Heart Transplantation: A Case Report and Literature Review},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16091010}
}
Kostenlos starten →